imatinib mesylate has been researched along with Hodgkin Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Gajendra, S; Gupta, SK; Sachdev, R; Sharma, A; Sharma, R; Sood, N | 1 |
| Bräuninger, A; Hansmann, ML; Renné, C | 1 |
| Baldini, L; F, FG; Ferrario, A; Goldaniga, M; Olivero, B; Radaelli, F; Rossi, F | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Aglietta, M; Anselmetti, G; Capaldi, A; Caravelli, D; Carnevale-Schianca, F; Coha, V; D'Ambrosio, L; Fizzotti, M; Gallo, S; Grignani, G; Obert, R; Palesandro, E; Rota-Scalabrini, D; Sangiolo, D | 1 |
| Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ | 1 |
| Kravchenko, SK; Moiseyeva, TN; Sharkunov, NN; Vinogradova, OY; Zybunova, EE | 1 |
| Georgakis, GV; Medeiros, LJ; Oyarzo, M; Rassidakis, GZ; Younes, A | 1 |
| Bräuninger, A; Hansmann, ML; Küppers, R; Renné, C; Willenbrock, K | 1 |
| Alkan, S; Amin, HM; Denning, MF; Ergin, M; Izban, KF; Martinez, RL; Saeed, S | 1 |
| Ahmadi, T; Buchdunger, E; Diehl, V; Kochanek, M; Re, D; Wickenhauser, C; Wolf, J | 1 |
1 review(s) available for imatinib mesylate and Hodgkin Disease
| Article | Year |
|---|---|
[Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].
Topics: Antineoplastic Agents; Autocrine Communication; B-Lymphocytes; Benzamides; Biopsy; Cell Line, Tumor; DNA Mutational Analysis; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Imatinib Mesylate; Lymph Nodes; Paracrine Communication; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Reed-Sternberg Cells; Signal Transduction; T-Lymphocytes; Transcription, Genetic | 2009 |
11 other study(ies) available for imatinib mesylate and Hodgkin Disease
| Article | Year |
|---|---|
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Topics: Centrosome; Chromosome Aberrations; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Time Factors | 2019 |
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Vinblastine | 2010 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Hodgkin Disease; Humans; Imatinib Mesylate; Male; Piperazines; Pneumonia; Pyrimidines; Radiography | 2011 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematologic Neoplasms; Hodgkin Disease; Humans; Ichthyosis; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Lung Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Parotid Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prednisone; Procarbazine; Pyrimidines; Retrospective Studies; Rituximab; Schizophrenia; Stomach Neoplasms; Vincristine | 2012 |
[Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisone; Procarbazine; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2012 |
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Flow Cytometry; Hodgkin Disease; Humans; Imatinib Mesylate; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphomatoid Papulosis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2004 |
Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma.
Topics: Autocrine Communication; Benzamides; Cell Survival; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Imatinib Mesylate; Immunohistochemistry; Paracrine Communication; Phosphotyrosine; Piperazines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2005 |
Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Caspases; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 5; Enzyme Inhibitors; Hodgkin Disease; Humans; Imatinib Mesylate; Immunohistochemistry; Lactams, Macrocyclic; Lymphoma, Large B-Cell, Diffuse; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinones; Receptor Protein-Tyrosine Kinases; Rifabutin; Translocation, Genetic; Tumor Cells, Cultured | 2001 |
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.
Topics: Benzamides; Cell Division; Drug Evaluation, Preclinical; Flow Cytometry; Hodgkin Disease; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stem Cell Factor; Tumor Cells, Cultured | 2002 |